Edwards Reports on Pascal TMVR System Clinical Studies

 

May 22, 2019—Edwards Lifesciences announced strategic clinical and regulatory milestones for the company's Pascal transcatheter valve repair system. The Pascal system received CE Mark approval and is available commercially in Europe. It is not approved in the United States.

At EuroPCR, held May 21–24 in Paris, France, Konstantinos Spargias, MD, presented 6-month data from the CLASP study of the Pascal system in patients with clinically significant mitral regurgitation (MR) despite optimal medical therapy.

The company also announced that the FDA has approved CLASP IIF, a prospective, multicenter, randomized, controlled pivotal trial studying the Pascal system.

As presented at EuroPCR, the 6-month CLASP data showed treatment with the Pascal system demonstrated sustained positive outcomes, including 81% of patients with mild (1+) or none/trace MR and 98% with < 2+ MR, with echo core lab adjudication. Additionally, patients experienced clinically and statistically significant improvements in functional status, exercise capability, and quality of life sustained at 6 months.

Edwards stated that these data build on the 30-day CLASP study, which also demonstrated a significant reduction in MR and improvements in quality of life measures. At 30 days, the major adverse events rate was low at 6.5%, and there was no incidence of stroke or myocardial infarction. These results were presented at DGK 2019, the German Society of Cardiology's 85th annual meeting, held April 24–27 in Mannheim, Germany.

The FDA-approved CLASP IIF will evaluate the safety and effectiveness of transcatheter mitral valve repair with Edwards' Pascal system compared with the MitraClip device (Abbott Vascular), for the treatment of moderate-to-severe (3+) or severe (4+) functional MR in symptomatic heart failure patients. The study is expected to begin enrolling in the next few months. The CLASP IID United States pivotal trial is currently enrolling patients with symptomatic primary MR, noted Edwards.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.